vedotin

1-12 of 12 Search Results for

Sort by

Sort Order Select

Book Chapter

Adverse Reactions of Antibody-Therapy for Primary Cutaneous Lymphomas: Rituximab, Brentuximab Vedotin, Alemtuzumab, and Mogamulizumab

Book: Adverse Reactions to Biologics

Series: Current Problems in Dermatology

Volume: 53

Published: 13 November 2017

10.1159/000478079

EISBN: 978-3-318-06101-7

... of autoimmune diseases, they had been exposed to other immunosuppressive agents. Brentuximab Vedotin [34,35] General Information Brentuximab vedotin is an antibody-drug conjugate consisting of a CD30-directed...

Open the PDF for Adverse Reactions of Antibody-Therapy for Primary Cutaneous Lymphomas: Rituximab, Brentuximab Vedotin, Alemtuzumab, and Mogamulizumab in another window

Book Chapter

References

Book: Adverse Reactions to Biologics

Series: Current Problems in Dermatology

Volume: 53

Published: 13 November 2017

EISBN: 978-3-318-06101-7

.... Arthritis Rheum 2009;60:3225-3228. 33. Al-Tawfiq JA, Banda RW, Daabil RA, Dawamneh MF: Progressive multifocal leukoencephalopathy (PML) in a patient with lymphoma treated with rituximab: a case report and literature review. J Infect Public Health 2015;8:493-497. 34. Brentuximab vedotin. Federal...

Book

Fast Facts: Peripheral T-cell Lymphoma: Unraveling the complexities of diagnosis and management

Published: 20 June 2019

10.1159/isbn.978-1-912776-19-1

EISBN: 978-1-912776-19-1

Open the PDF for Fast Facts: Peripheral T-cell Lymphoma: Unraveling the complexities of diagnosis and management in another window

Book

Adverse Reactions to Biologics

Series: Current Problems in Dermatology

Volume: 53

Published: 13 November 2017

10.1159/isbn.978-3-318-06101-7

EISBN: 978-3-318-06101-7

Book Chapter

References

Book: Tumors in Adolescents and Young Adults

Series: Progress in Tumor Research

Volume: 43

Published: 08 September 2016

EISBN: 978-3-318-05912-0

... event-free survival in patients with Hodgkin lymphoma. Blood 2012;119:1665-1670. 67. Younes A, Bartlett NL, Leonard JP, et al: Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med 2010;363:1812-1821. 68. Moskowitz CH, Nademanee A, Masszi T, et al: Brentuximab vedotin...

Book Chapter

Lymphoma in Adolescents and Young Adults

Book: Tumors in Adolescents and Young Adults

Series: Progress in Tumor Research

Volume: 43

Published: 08 September 2016

10.1159/000447080

EISBN: 978-3-318-05912-0

... rates of 74 and 92.5%, respectively [ 43 ] whereas adult patients are generally treated according to protocols designed for DLBCL mostly with anthracycline-containing regimens (CHOP, CHOEP (CHOP + etoposide)) [ 41 ]. Several promising targeted agents such as CD30 immunoconjugate brentuximab vedotin...